A single point mutation in the DNA gyrase A protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complex
about
Emerging mechanisms of fluoroquinolone resistanceMechanism of differential activities of ofloxacin enantiomersBreakage-reunion domain of Streptococcus pneumoniae topoisomerase IV: crystal structure of a gram-positive quinolone targetA mutation in Escherichia coli DNA gyrase conferring quinolone resistance results in sensitivity to drugs targeting eukaryotic topoisomerase IIImportance of the fourth alpha-helix within the CAP homology domain of type II topoisomerase for DNA cleavage site recognition and quinolone action.Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity.Sparfloxacin resistance in clinical isolates of Streptococcus pneumoniae: involvement of multiple mutations in gyrA and parC genesEffects of mutations in GrlA of topoisomerase IV from Staphylococcus aureus on quinolone and coumarin activity.gyrA mutations associated with fluoroquinolone resistance in eight species of Enterobacteriaceae.A mutational analysis and molecular dynamics simulation of quinolone resistance proteins QnrA1 and QnrC from Proteus mirabilis.Anti-tubercular drug designing by structure based screening of combinatorial libraries.The PK-PD Relationship and Resistance Development of Danofloxacin against Mycoplasma gallisepticum in An In Vivo Infection Model.Analysis by PCR and direct DNA sequencing of gyrA mutations associated with fluoroquinolone resistance in Enterococcus faecalis.gyrA mutations in quinolone-resistant isolates of the fish pathogen Aeromonas salmonicida.Association between double mutation in gyrA gene of ciprofloxacin-resistant clinical isolates of Escherichia coli and MICsAlterations in DNA gyrase and topoisomerase IV in resistant mutants of Clostridium perfringens found after in vitro treatment with fluoroquinolones.Mechanisms and frequency of resistance to premafloxacin in Staphylococcus aureus: novel mutations suggest novel drug-target interactionsNew mutation in parE in a pneumococcal in vitro mutant resistant to fluoroquinolones.DNA gyrase-mediated natural resistance to fluoroquinolones in Ehrlichia spp.Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus.Induction of prophages of enterohemorrhagic Escherichia coli O157:H7 with norfloxacin.parC mutations in fluoroquinolone-resistant Borrelia burgdorferi.The interaction of drugs with DNA gyrase: a model for the molecular basis of quinolone action.Quinolone Resistance: Older Concepts and Newer Developments.Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes.Topoisomerase II binds to ellipticine in the absence or presence of DNA. Characterization of enzyme-drug interactions by fluorescence spectroscopy.Role of the extended alpha4 domain of Staphylococcus aureus gyrase A protein in determining low sensitivity to quinolones.Topoisomerase targeting with and resistance to gemifloxacin in Staphylococcus aureusClinical importance and epidemiology of quinolone resistance.Dead bugs don't mutate: susceptibility issues in the emergence of bacterial resistance.Development of multiple-antibiotic-resistant (Mar) mutants of Pseudomonas aeruginosa after serial exposure to fluoroquinolones.DNA gyrase mutations in quinolone-resistant clinical isolates of Neisseria gonorrhoeae.Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli.Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.A novel, double mutation in DNA gyrase A of Escherichia coli conferring resistance to quinolone antibiotics.Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV purified from Staphylococcus aureus.Yeast recombination pathways triggered by topoisomerase II-mediated DNA breaks.Analysis of the gyrA gene of clinical Yersinia ruckeri isolates with reduced susceptibility to quinolones.Drug interactions with Bacillus anthracis topoisomerase IV: biochemical basis for quinolone action and resistance.Effect of magnesium complexation by fluoroquinolones on their antibacterial properties.
P2860
Q24644842-E605C217-F038-4983-8306-7FB2558C3D3BQ24675769-C671CBA0-052D-4E84-8372-B467EE824A92Q27303056-33FD0EBB-9ACB-4370-A488-DB20B630E82FQ30448695-56236257-9546-43BD-88CF-6808766A206BQ30453068-D05366E9-E90A-42BC-8A2D-58C51CDD7F11Q33690598-360090DC-BFC8-471D-BD92-4E7298FCBC7FQ33695625-E37D0432-D483-4B72-8FF8-FAA1AADDD28CQ33698247-887B7E77-623E-4100-ABA7-80D95A64E167Q33699643-A2462A60-0EA8-4EB7-B1F9-37090CD396DBQ33713271-B4E17AC8-B683-4A86-B200-05A55EB104C8Q33720784-DCE20D22-7057-4A1B-8206-F706909DC178Q33736566-ABF3C8BE-3718-46E6-B922-47CFD1CC6FABQ33758823-686F8B23-4630-4A67-BCE9-784A7F035B92Q33761909-EC41BE93-5FBA-4EDE-BD0D-7DAA74710667Q33762110-DDA51602-0BE7-404A-B71D-5B9752B3C8D9Q33805682-5DF9066A-BD97-492C-8175-8A86F7A5957DQ33980991-BA6D88FA-CE10-4363-A82B-B2B9383789AEQ33981750-0D836D6B-4ACE-4505-B2CE-2BC3897B9A3EQ33982545-24218FB4-88B3-431B-8573-CEE0CC73EF65Q33983092-974222F2-214E-41DC-89F1-A88AD98FB55BQ33991692-A5F8950F-E3D1-4A24-8C0B-F700426AA9ADQ34077147-6C9B464A-EFC6-43CA-AAC2-82F9737318E4Q34092838-DFDBFBFE-F246-4449-A58A-4CB7F236D1BBQ34140894-1462138B-1FA8-4AA4-AC61-4B61D02DB424Q34301585-5BFAAB5B-1455-4288-BA9C-C0AC5E7BF437Q34314426-A3FAB906-2B4B-4B4E-A8CF-263425AEEC4EQ34352135-694D912F-95B8-448B-ACF8-9A2D7F75EFB0Q34725095-14E5D9A6-A878-4CC3-A109-CC32A375F356Q34838791-0A895FAC-792C-4343-8820-EA3969EF8A77Q35047705-29C1CD8B-DA13-4AC4-8EEA-550B789945AEQ35111809-29D6F2D3-D766-4968-9C17-23F90F3E7F80Q35112033-AE8D674D-7C65-46B2-8C2C-5871535D9321Q35123629-B743372D-C5ED-4FC6-927E-1CAC3AF93BDAQ35126142-D6FD2E75-87FA-4351-8884-28CE8EEABD31Q35131092-2930314C-BE97-41D2-BA8A-9CC10E136C84Q35138781-69CA8D1A-0558-4CE1-96D9-BE32368F5F89Q35222177-CC92C658-376E-4672-A164-1FDA93E57C85Q35539531-E92ADE39-4936-40CA-B397-A2D7438649E6Q35682250-7B012007-6DF4-4E6D-B0F3-F4BDEC3D4414Q35823176-758222C5-4B74-4F09-9F31-44F47326F0F5
P2860
A single point mutation in the DNA gyrase A protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complex
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
A single point mutation in the ...... ones to the gyrase-DNA complex
@en
A single point mutation in the ...... nes to the gyrase-DNA complex.
@nl
type
label
A single point mutation in the ...... ones to the gyrase-DNA complex
@en
A single point mutation in the ...... nes to the gyrase-DNA complex.
@nl
prefLabel
A single point mutation in the ...... ones to the gyrase-DNA complex
@en
A single point mutation in the ...... nes to the gyrase-DNA complex.
@nl
P2860
P356
P1476
A single point mutation in the ...... ones to the gyrase-DNA complex
@en
P2093
Willmott CJ
P2860
P304
P356
10.1128/AAC.37.1.126
P407
P577
1993-01-01T00:00:00Z